Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rare Disease Roundtable: How Rare Is Too Rare?

Executive Summary

Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.

Advertisement

Related Content

Rare Disease Roundtable: Dealing With Pricing Pressure
When The Trial Site Is A Living Room: Pharma Explores Virtual Research Options
Orphan Drugs Compose Majority Of Novel US Approvals For First Time Ever In 2018
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Mereo Halts Plans For US Listing
Ultragenyx Gets Second Drug Approval; Crysvita With Kyowa Hakko Kirin
Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124709

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel